Zydus receives final approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Bisoprolol Fumarate and Hydrochlorothiazide tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, 10 mg/6.25 mg (USRLD: Ziac® tablets).

Bisoprolol Fumarate and hydrochlorothiazide combination is indicated to treat high blood pressure (hypertension). The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Bisoprolol Fumarate and Hydrochlorothiazide tablets had annual sales of USD 27.1 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022).

The group now has 331 approvals and has so far filed over 428* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 30th June 2022)

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 450.85 as compared to the previous close of Rs. 439.80. The total number of shares traded during the day was 57411 in over 2568 trades.

The stock hit an intraday high of Rs. 453.80 and intraday low of 441.40. The net turnover during the day was Rs. 25764882.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA BisoprololFumarate Hydrochlorothiazide Tablets